

09/790,483

Amendment to the Claims:

1.-19. (Withdrawn)

1/20.

(Currently Amended) A method for treating a cancer patient, comprising:

administering to the cancer patient ~~a DNA methylation inhibitor~~ decitabine at a dose ranging from 1 mg/m<sup>2</sup> per day to 20 mg/m<sup>2</sup> per day, in combination with a therapeutically effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation, wherein the cancer is selected from the group consisting of ovarian, breast, prostate, gastric, lung, pancreas and colon cancer and is refractory to the treatment of the anti-neoplastic agent alone.

21. (Cancelled)

22. (Withdrawn)

23. (Cancelled)

24. (Withdrawn)

2/25.

(Previously Amended) A method for treating a cancer patient, comprising:

administering to the cancer patient decitabine at a dose ranging from 1 mg/m<sup>2</sup> per day to 20 mg/m<sup>2</sup> per day, in combination with a therapeutically effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation, wherein the cancer is a non-small cell lung cancer.

26.-27. (Withdrawn)

3/28.

(Currently Amended) The method of claim <sup>1</sup>/<sub>20</sub>, wherein the ~~DNA methylation inhibitor~~ is decitabine and the anti-neoplastic agent is cisplatin or carboplatin.

4/29.

(Currently Amended) The method of claim <sup>1</sup>/<sub>20</sub>, wherein the ~~DNA methylation inhibitor~~ decitabine is administered subcutaneously or intravenously.

30.-32. (Cancelled)